Very Late-Onset Cytomegalovirus DNAemia in Asymptomatic Kidney Transplant Recipients: Incidence, Risk Factors and Outcome.

2014 ◽  
Vol 98 ◽  
pp. 765 ◽  
Author(s):  
L. Couzi ◽  
I. Garrigue ◽  
T. Bachelet ◽  
J. Moreau ◽  
J. Dechanet-Merville ◽  
...  
Keyword(s):  
Risk Factors ◽  
Kidney Transplant ◽  
Late Onset ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Incidence Risk

Risk Factors for Late-Onset Cytomegalovirus Infection or Disease in Kidney Transplant Recipients

2014 ◽  
Vol 97 (5) ◽  
pp. 569-575 ◽  
Author(s):  
Alainna J. Jamal ◽  
Shahid Husain ◽  
Yanhong Li ◽  
Olusegun Famure ◽  
S. Joseph Kim
Keyword(s):  
Risk Factors ◽  
Kidney Transplant ◽  
Cytomegalovirus Infection ◽  
Late Onset ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Medication Errors and Adverse Drug Events in Kidney Transplant Recipients: Incidence, Risk Factors, and Clinical Outcomes

2012 ◽  
Vol 32 (12) ◽  
pp. 1053-1060 ◽  
Author(s):  
David J. Taber ◽  
Nicole A. Pilch ◽  
Charles F. Bratton ◽  
John W. McGillicuddy ◽  
Kenneth D. Chavin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Outcomes ◽  
Kidney Transplant ◽  
Medication Errors ◽  
Adverse Drug Events ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Incidence Risk

scholarly journals Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin

2020 ◽  
Vol 7 ◽  
pp. 205435812096406
Author(s):  
Rachel Jeong ◽  
Robert R. Quinn ◽  
Krista L. Lentine ◽  
Pietro Ravani ◽  
Feng Ye ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Graft Failure ◽  
Antithymocyte Globulin ◽  
Graft Function ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Incidence Risk

Background: Kidney transplant recipients are given induction therapy to rapidly reduce the immune response and prevent rejection. Guidelines recommend that an interleukin-2 receptor antibody (basiliximab) be the first-line agent and that a lymphocyte-depleting agent (antithymocyte globulin [ATG]) be reserved for those at high immunologic risk. Objective: To determine the incidence, risk factors, and outcomes for patients who receive both basiliximab and ATG for induction compared to either agent alone. Design: Retrospective cohort study. Setting: We used the transplant electronic medical record at the University of Alberta Hospital in Edmonton, Canada. Patients/samples/participants: We included incident adult kidney transplant recipients from 2013 to 2018. Measurements: We measured baseline characteristics, type, and dose of induction therapy used, estimated glomerular filtration rate (eGFR) at 1-year posttransplant, and outcomes of all-cause graft failure, death-censored graft failure, all-cause mortality, and death with a functioning graft. Methods: Differences between induction groups were compared using chi-square test for categorical variables and Kruskal-Wallis tests for continuous variables. We performed multivariable logistic regression modeling with type of induction therapy as the dependent variable and the case-level factors as the predictors (adjusted odds ratio). We estimated the Kaplan-Meier failure functions and used log-rank tests to assess statistical significance of differences in unadjusted incidence across induction therapy types. We compared cumulative incidence functions using a Fine and Gray competing risk regression model. Results: In all, 430 kidney transplant recipients were followed for a mean of 3.9 years (standard deviation 1.5). Of these, 71% (n = 305) received basiliximab alone, 22% (n = 93) received ATG alone, and 7% (n = 32) received both basiliximab and ATG. After adjusting for age and sex, compared to the basiliximab alone group, patients were more likely to receive dual-induction therapy if they were sensitized (calculated panel reactive antibody ≥80%), had diabetes mellitus or peripheral vascular disease, or experienced delayed graft function. Compared to the ATG alone group, the dual-induction therapy group had worse graft function at 1 year (mean eGFR 42 vs. 59 mL/min/1.73 m2, P = .0008) and an increased risk of all-cause graft failure (31% vs. 13%, P = .02) and death-censored graft failure (16% vs. 4%, P = .03). Limitations: There is a risk of confounding by indication, as patients who received dual-induction therapy likely had worse outcomes due to the indication for dual-induction therapy (such as delayed graft function). Conclusions: In our study, 1 out of 10 recipients who were treated with basiliximab also received ATG for induction therapy. These patients experienced worse outcomes than those treated with ATG alone. Trial registration: Not applicable (cohort study).

scholarly journals POS-704 LYMPHOCELE IN KIDNEY TRANSPLANT RECIPIENTS: INCIDENCE, RISK FACTORS AND TREATMENT A SINGLE CENTER EXPERIENCE

2021 ◽  
Vol 6 (4) ◽  
pp. S307
Author(s):  
M. MOJAAT ◽  
M. Ben salem ◽  
I. Chemli ◽  
M. Hamouda ◽  
I. Handous ◽  
...  
Keyword(s):  
Risk Factors ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Single Center ◽  
Kidney Transplant Recipients ◽  
Single Center Experience ◽  
Incidence Risk

scholarly journals Incidence, Risk Factors, and Outcomes of Clostridium difficile Infections in Kidney Transplant Recipients

2018 ◽  
Vol 102 (9) ◽  
pp. 1576-1581 ◽  
Author(s):  
George J. Li ◽  
Justin Trac ◽  
Shahid Husain ◽  
Olusegun Famure ◽  
Yanhong Li ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clostridium Difficile ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Incidence Risk

scholarly journals Surgical site complications in kidney transplant recipients: incidence, risk factors and outcomes in the modern era

2021 ◽  
Vol 64 (6) ◽  
pp. E669-E676
Author(s):  
Rebecca Bic Kay Wong ◽  
Michelle Minkovich ◽  
Olusegun Famure ◽  
Yanhong Li ◽  
Jason Young Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Incidence Risk ◽  
Surgical Site Complications ◽  
Modern Era

scholarly journals SP740LYMPHOCELES IN KIDNEY TRANSPLANT RECIPIENTS: INCIDENCE, RISK FACTORS AND IMPACT ON LONG-TERM OUTCOMES

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii392-iii392
Author(s):  
Lukas Lehner ◽  
Arnim Hohberger ◽  
LIsanne Marschke ◽  
Tanja Flaig ◽  
Fabian Halleck ◽  
...  
Keyword(s):  
Risk Factors ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Long Term Outcomes ◽  
Incidence Risk

Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome

2015 ◽  
Vol 17 (4) ◽  
pp. 497-509 ◽  
Author(s):  
B. Viot ◽  
I. Garrigue ◽  
B. Taton ◽  
T. Bachelet ◽  
J.-F. Moreau ◽  
...  
Keyword(s):  
Risk Factors ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Post Transplantation ◽  
Incidence Risk
Sign in / Sign up

Export Citation Format

Share Document